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Abstract
Objective: Brain imaging studies of structural abnormalities in OCD have yielded inconsistent 
results, partly due to limited statistical power, clinical heterogeneity, and methodological 
differences. Here, we perform meta- and mega-analyses comprising the largest study of cortical 
morphometry in OCD ever undertaken.
Methods: T1-weighted MRI scans of 1905 OCD patients and 1760 healthy controls from 27 sites 
worldwide were processed locally using FreeSurfer to assess cortical thickness and surface area. 
Effect sizes for differences between patients and controls, and associations with clinical 
characteristics, were calculated using linear regression models controlling for age, sex, site, and 
intracranial volume.
Results: In adult OCD patients versus controls, we found significantly lower surface area of the 
transverse temporal cortex and a thinner inferior parietal cortex. Medicated adult OCD patients 
also showed thinner cortices throughout the brain. In pediatric OCD patients versus controls, we 
found significantly thinner inferior and superior parietal cortices, but none of the regions analyzed 
showed significant differences in surface area. However, medicated pediatric OCD patients had 
lower surface area in frontal regions. Cohen’s d effect sizes varied between −0.10 and −0.33.
Conclusion—The parietal cortex was consistently implicated both in adults and children with 
OCD. More widespread cortical thickness abnormalities were found in medicated adult OCD 
patients, and more pronounced surface area deficits (mainly in frontal regions) were found in 
medicated pediatric OCD patients. These cortical measures represent distinct morphological 
features and may be differentially affected during different stages of development and illness, and 
possibly moderated by disease profile and medication.
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Introduction
Disease models of obsessive-compulsive disorder (OCD) propose that abnormalities in the 
cortico-striato-thalamo-cortical (CSTC) circuits are key to the pathophysiology of OCD. 
More recent findings also implicate the involvement of fronto-limbic and fronto-parietal 
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regions in pediatric and adult OCD (1–3). An important limitation of brain imaging research 
is the typically small samples that limit sensitivity and presumably contributing to the lack 
of reproducibility and reliability (4). This issue may be partially addressed by the use of 
meta- and mega-analysis of multiple study samples. We therefore initiated the OCD working 
group within the Enhancing Neuro-Imaging Genetics through Meta-Analysis (ENIGMA) 
consortium (5) in which researchers around the world collaborate to boost statistical power, 
with the aim of elucidating brain abnormalities in OCD.
Recently, we performed meta- and mega-analyses on data from 3589 individuals and 
reported subcortical volume differences between OCD patients and healthy controls that 
were related to clinical characteristics. Distinct subcortical volume abnormalities were 
detected in adults and children with OCD. Adult OCD patients had significantly smaller 
hippocampal and larger pallidal volumes. The smaller hippocampal volume seemed to be 
driven by comorbid depression and an adult illness onset. The larger pallidal volume was 
more pronounced in adult OCD patients with a childhood illness onset. Children with OCD 
had larger thalamic volumes compared to control children (6).
With regard to the cortex, prior magnetic resonance imaging (MRI) studies consistently 
show abnormalities in dorsomedial prefrontal and anterior cingulate cortices (ACC) (7–10), 
findings that are supported by mega-analyses from the OCD Brain Imaging Consortium (11; 
12). Also abnormalities in fronto-parietal and temporo-parietal regions have been reported 
(10; 12–14). Findings regarding the orbitofrontal cortex (OFC) (8; 11; 15) and operculum 
have been rather inconsistent (8; 10; 11; 13; 16). These inconsistencies may be partially 
explained by differences in processing protocols, limited statistical power, and clinical 
heterogeneity related to variation in disease profile and developmental stage.
Most of these studies were predominantly based on volumetric measures using voxel-based 
morphometry (VBM). Volumetric measures, however, depend on a combination of changes 
in gray matter thickness and surface area (17). Fewer studies have used surface-based 
methods to generate detailed maps of cortical thickness and surface area. These measures 
represent distinct features of cortical morphometry that are somewhat genetically 
independent and are driven by different neurobiological processes (18). Studying these 
properties independently will make it easier to interpret the cortical abnormalities reported 
in OCD in the context of the postulated neurodevelopmental basis for OCD (19) 
(Supplementary Information SI1).
Here we performed the largest coordinated worldwide study of cortical measures in patients 
with OCD compared to healthy controls. We extracted cortical thickness and surface area 
estimates of 1905 OCD patients and 1760 healthy controls, using harmonized data 
processing and analysis strategies across 27 sites. We also aimed to establish the potential 
modulating effects of demographic and clinical characteristics. Based on the prior literature, 
we expected lower cortical thickness in ACC, OFC, dorsomedial prefrontal cortex (dmPFC) 
and parietal regions, in OCD patients compared to healthy controls. In addition, we explored 
the cortical surface area profile in OCD.
Boedhoe et al. Page 2















The ENIGMA-OCD working group includes 38 data sets from 27 international research 
institutes, with neuroimaging and clinical data from OCD patients and typically developing 
healthy control subjects (i.e., free of psychopathology), including both children and adults 
(participating sites are mapped in Supplementary Figure S1). Six (i.e. the entire OBIC 
sample) out of these 38 data sets were identical to those included in the OBIC mega-
analyses using VBM (11) and vertex-based FreeSurfer (12). We defined adults as individuals 
aged ≥18 years and children as individuals aged <18 years. The split at the age of 18 
followed from a natural selection of the age ranges used in these samples, as most samples 
used the age of 18 years as a cut-off for inclusion. Each sample’s demographic and clinical 
characteristics are detailed in Supplementary Tables S1 and S2. In total, we analyzed data 
from 3665 subjects including 1905 OCD patients (407 children and 1498 adults) and 1760 
control subjects (324 children and 1436 adults). All local institutional review boards 
permitted the use of measures extracted from the anonymized data for mega-analyses.
Image Acquisition and Processing
Structural T1-weighted MRI brain scans were acquired and processed locally. Image 
acquisition parameters for each site are given in Supplementary Table S3. All cortical 
parcellations were performed with the fully automated segmentation software FreeSurfer, 
version 5.3 (20), following standardized ENIGMA protocols to harmonize analyses and 
quality control procedures across multiple sites (see http://enigma.usc.edu/protocols/
imaging-protocols/). Segmentation of 68 (34 left and 34 right) cortical gray matter regions 
based on the Desikan-Killiany atlas (21) and two whole-hemisphere measures were visually 
inspected and statistically evaluated for outliers. Details on image exclusion criteria and 
quality control are presented in Supplementary Information SI1.
Statistical framework
We performed both a meta-analysis (i.e., using group statistics from the independent studies) 
and mega-analysis (i.e., pooling extracted measures from individual subjects across sites, 
while adjusting for site effects) to be consistent with our prior paper. In this manuscript we 
will focus on the mega-analysis. See Supplementary Information SI3 for methods, results 
and discussion of the meta-analysis.
We examined differences between OCD patients and controls within a mega-analytical 
framework by pooling the extracted cortical thickness and surface area measures from each 
site. Each of the 70 cortical regions of interest (68 regions and two whole-hemisphere 
average thickness or total surface area measures) served as the outcome measure and a 
binary indicator of diagnosis as the predictor of interest in multiple linear regression models. 
All cortical thickness models were adjusted for age and sex; cortical surface area models 
were corrected for intracranial volume (ICV, see Supplementary Information SI1), age, age2, 
sex, age-by-sex, and age2-by-sex, to account for any higher-order effects on cortical surface 
area of age and sex as well as head size, which do not appear to be detectable for cortical 
thickness measures (22). Additionally, all models were also adjusted for site, coded by using 
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dummy variables. Effect size estimates were calculated using the Cohen’s d metric 
computed from the t-statistic of the diagnosis indicator variable from the regression models. 
Similarly, for models testing interactions (i.e., sex-by-diagnosis and age-by-diagnosis), a 
multiplicative predictor was the predictor of interest with the main effect of each predictor 
included in the model. The effect size was calculated using the same procedure.
To detect potentially different effects of disease with age, we performed all analyses 
separately for pediatric and adult participants. We performed stratified analyses comparing 
the medicated group and unmedicated group of OCD patients separately to controls and to 
each other. Likewise, stratified analyses were performed to investigate effect of comorbid 
major depressive disorder, comorbid anxiety disorders, and OCD symptom dimensions 
(using the Yale-Brown Obsessive Compulsive Scale [Y-BOCS] and the Children’s Yale-
Brown Obsessive Compulsive Scale [CY-BOCS] symptom checklist; see Supplementary 
Information SI2). To study the neurodevelopmental aspects of illness within the adult 
samples, we performed separate stratified analyses comparing childhood-onset OCD patients 
(onset <18 years) and adult-onset OCD patients (onset ≥18 years). Furthermore, we 
examined associations with age at onset, illness duration and illness severity (using the total 
severity score from the (C)Y-BOCS (23; 24)) as continuous variables. In these analyses, 
effect sizes were expressed as partial-correlation Pearson’s r after removing nuisance 
variables (age, sex, site and ICV). Throughout the manuscript, we report P-values corrected 
for multiple comparisons using the Benjamini-Hochberg procedure to ensure a false-
discovery rate (FDR) limited at 5% for 70 cortical measures.
Results
An overview of the demographic and clinical characteristics of the pooled samples is 
provided in Table 1.
Mega-analysis
Cortical thickness and surface area differences between OCD patients and 
controls
Adults:  Lower cortical thickness was observed in adult OCD patients (N=1498) compared 
to controls (N=1436) in the bilateral inferior parietal cortex (Cohen’s d effect size −0.14; 
Figure 1 and Supplementary Table S4). In all tables, regions are listed in order of effect size 
(strongest to weakest). A lower surface area was observed in the left transverse temporal 
cortex (Cohen’s d −0.16; Supplementary Table S5 and Figure S2). None of the regions 
showed significant sex-by-diagnosis or age-by-diagnosis interaction effects.
Children:  We found significantly thinner cortices in pediatric OCD patients (N=407) 
compared to controls (N=324) in bilateral superior parietal and left inferior parietal cortices 
(Figure 2) and left lateral occipital cortex (Cohen’s d between −0.24 and −0.31; 
Supplementary Table S6). None of the regions analyzed showed significant differences in 
cortical surface area or evidence of sex-by-diagnosis or age-by-diagnosis interaction effects 
(Supplementary Table S7).
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Influence of medication on cortical thickness and surface area
Adults:  Left and right hemisphere cortical thickness was lower in medicated OCD patients 
(N=646) compared to controls (N=1436). Regionally, we found significantly thinner cortices 
in frontal, temporal, parietal and occipital regions of adult medicated OCD patients (Cohen’s 
d between −0.10 and −0.26; Figure 3 and Supplementary Table S8a). We did not detect 
significant differences in cortical thickness in unmedicated OCD patients (N=831) compared 
to controls (Supplementary Table S8b). Medicated OCD patients compared to unmedicated 
patients showed lower cortical thickness in frontal, temporal and parietal regions (Cohen’s d 
between −0.13 and −0.21; Supplementary Table S8c and Figure S3). Similar to the main 
group comparison, we found lower surface area of the left transverse temporal cortex in 
medicated OCD patients versus controls (Cohen’s d −0.20; Supplementary Table S9a and 
Figure S4). We did not detect differences in surface area in unmedicated OCD patients 
compared to controls and when comparing medicated and unmedicated patients directly 
(Supplementary Tables S9b–c).
Children:  Compared to controls (N=324), medicated children with OCD (N=183) showed 
lower cortical thickness of the bilateral inferior parietal and superior parietal cortices and left 
lateral occipital cortex (Cohen’s d ~−0.31; Supplementary Table S10a and Figure S5). We 
did not detect significant differences in cortical thickness in unmedicated pediatric OCD 
patients (N=222) compared to controls and when comparing medicated with unmedicated 
patients (Supplementary Tables S10b–c). More widespread surface area differences were 
detected when comparing medicated pediatric OCD patients to controls mainly in several 
frontal regions (Cohen’s d between −0.27 and −0.33; Supplementary Table S11a and Figure 
4). No differences in surface area were observed when comparing unmedicated patients to 
controls (Supplementary Table S11b). We did observe lower surface area of the right lingual 
(Cohen’s d −0.34) and pericalcarine (Cohen’s d −0.40) cortices in medicated compared to 
unmedicated pediatric OCD patients (Supplementary Table S11c and Figure S6).
Influence of comorbidities on cortical thickness and surface area—We did not 
detect any associations between cortical thickness or surface area and current comorbid 
depression or anxiety disorder in adults (respectively N=167 and N=224) or in children 
(respectively N=29 and N=132). These numbers, however, are too small because of the lack 
of systematic assessment of comorbidities in some samples and reflect an underestimation of 
comorbidity due to exclusion of comorbid cases in other samples. See Supplementary 
Information SI4 for full details.
Influence of symptom dimensions on cortical thickness and surface area
Adults:  Regression analyses within OCD patients on symptom dimensions (N=1214) 
showed no associations between the presence of a particular symptom dimension and 
cortical thickness or surface area with any of the regions.
Children:  Pediatric OCD patients with ordering and symmetry symptoms (N=181) showed 
a higher surface area of the left cuneus (Cohen’s d 0.49; Supplementary Table S20 and 
Figure S14). None of the regions analyzed showed significant differences in cortical 
thickness or evidence of associations with the other symptom dimensions.
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Influence of age at onset and illness duration on cortical thickness and 
surface area—Adult OCD patients with an adult illness onset (N=775) compared to 
controls (N=1436) showed thinner cortices in left and right hemisphere overall. Regionally, 
we observed thinner cortices in frontal and temporal regions of adult-onset patients (Cohen’s 
d between −0.11 and −0.16; Supplementary Table S21a and Figure S15). We also found 
lower surface area of the left transverse temporal cortex (Cohen’s d −0.17) and the left pars 
opercularis (Cohen’s d −0.14) in adult OCD patients with an adult illness onset 
(Supplementary Table S22a and Figure S16). We did not detect significant differences in 
cortical thickness or surface area in adult OCD patients with a childhood illness onset 
(N=646) compared to controls or when comparing adult-onset and childhood-onset patients 
directly (Supplementary Tables S21b–c and Supplementary Tables S22b–c).
Furthermore, we did not observe any significant linear (Supplementary Tables S23–S26) or 
quadratic (Supplementary Tables S37–S40) associations between age at onset or illness 
duration as continuous variables and cortical thickness or surface area changes in the adult 
(N=1419) or pediatric (N=708) OCD groups.
Association between illness severity and cortical thickness and surface area
—We did not detect any significant linear (Supplementary Tables S27–S28) or quadratic 
(Supplementary Tables S41–S42) associations in either the adult (N=1453) or the pediatric 
(N=404) OCD patients between illness severity ([C]Y-BOCS) and cortical thickness or 
surface area.
Meta-analysis
Decreased cortical thickness of the inferior parietal cortex was present in adult patients with 
OCD compared to healthy controls, but at a less stringent significance threshold (Cohen’s 
d≈ −0.14; p <0.01, uncorrected). The meta-analysis did show significant widespread effects 
of medication on cortical thickness and a lower surface area of the transverse temporal 
cortex in adult OCD patients. The pediatric meta-analysis, also on a less stringent 
significance threshold (Cohen’s d≈ −0.31; p <0.05, uncorrected), showed decreased cortical 
thickness of the inferior and superior parietal cortex in children with OCD. In addition, field 
strength did not significantly explain the effect size estimates of cortical thickness or surface 




This is the largest neuroimaging study conducted on cortical measures in OCD to date. We 
found that the parietal cortex was consistently implicated both in adult and pediatric OCD, 
which is consistent with prior VBM and FreeSurfer studies (12; 25). Lower cortical 
thickness of the inferior parietal cortex in adult OCD patients compared to controls is in 
accordance with results reported by Kuhn et al. (10) and the OBIC consortium (12). Lower 
cortical thickness of the inferior and superior parietal cortex in children with OCD is a novel 
finding. The only other study of cortical thickness in pediatric OCD found lower cortical 
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thickness of another parietal region, the supramarginal gyrus (29). Other imaging studies 
have reported lower gray matter volume in the parietal lobe, especially in the angular gyrus 
of the inferior parietal lobe in children and adults with OCD (25; 30).
In contrast to previous mega-analyses from the OBIC consortium, we did not find cortical 
thickness abnormalities in the OFC, ACC, or dmPFC. Six (i.e. the entire OBIC sample) out 
of our 38 data sets were identical to those included in the OBIC mega-analysis. Apart from a 
much larger sample size including samples from more different countries, no discrepancies 
between demographic and clinical characteristics could be found between this sample and 
the OBIC sample. Thus these inconsistencies are likely to reflect differences in analysis 
methods and the overall sample size. While FreeSurfer measures thickness and surface area 
separately, it segments whole structures based on probabilistic information from a 
predefined atlas (20), compared to VBM’s voxel-wise registration (26). Mainly global or 
regional differences in structure can be inferred from these atlas-based FreeSurfer analyses, 
as opposed to local morphology as with VBM. Moreover, the FreeSurfer mega-analysis of 
the OBIC consortium (12) was conducted using vertex-based analyses rather than the atlas-
based approach we used in the current study. It is thus possible that certain abnormalities on 
vertex level are not detectable when averaging data across whole regions (27). Notably, the 
OBIC sample included only 1.5T scans and was processed using an older version of 
FreeSurfer V4.5. Future research using higher resolution parcellation (e.g., (28)) is 
necessary to validate our results.
In the present study we had sufficient statistical power to detect subtle (Cohen’s d, −0.15 to 
−0.31) cortical abnormalities in OCD (Supplemental Information SI5). Large-scale studies 
such as ours are well powered to distinguish consistent, generalizable findings from false 
positives. Structural MRI provides a crude and indirect measure of putative alterations at the 
molecular level, but these subtle abnormalities in the parietal cortex may still be relevant 
from a pathophysiological perspective (31). These results provide insight into what systems 
are affected, and promote further research to evaluate specific pathways implicated in the 
pathophysiology of OCD.
Neuroimaging studies of normal brain maturation demonstrate a continuous increase in 
parietal thickness reaching peak values around age 12, followed by a steady decrease over 
subsequent decades (32). In terms of neurodevelopmental abnormalities, our results may be 
cautiously interpreted as evidence for a relationship between the expression of OCD and 
disturbances in factors influencing radial cortical expansion, which influences gray matter 
thickness rather than factors influencing the tangential expansion that determines the overall 
surface area (33). In this context, our results could indicate an altered cortical maturation in 
OCD resulting in a thinner parietal cortex in early childhood, persisting into adulthood, 
although further confirmatory work using longitudinal samples is needed.
Cognitive studies in OCD suggest that the parietal cortex plays a significant role in 
accounting for the cognitive deficits seen in OCD patients. Parietal lobe activation may be 
related to attention, set shifting, planning and response inhibition, which are also reported to 
be impaired in OCD patients (34) and reflect a lack of cognitive flexibility that may be 
related to the repetitive nature of OCD symptoms and behaviors. The inferior parietal cortex 
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is an important node in both the fronto-parietal network and the default mode network. 
Several studies reported altered connectivity within these networks in patients with OCD 
(35–37). The phenomenology of the disorder is consistent with the idea of a disrupted 
relationship between ongoing internal thought and external information, in that patients 
often excessively focus on internally generated fears that are inconsistent with evidence 
present in the external environment (38).
We reported lower cortical thickness of numerous regions throughout the brain of medicated 
adult OCD patients. These medication effects partially overlap with prior research (12). 
Although these findings need to be interpreted with caution, it has been suggested that 
antidepressants might modulate plasticity in the brain (39). Additionally, post-hoc analyses 
suggest that these medication effects are strongest in those patients taking antidepressants 
with adjuvant antipsychotics (Supplementary Tables S36a–c and Supplementary Info SI4). 
Alternatively, those patients taking medication could represent a more clinically severe 
cohort that manifests these morphometric abnormalities. Results may have been confounded 
by a higher illness severity and a higher percentage of comorbid depression of the medicated 
adult OCD group (Supplementary Table S35). However, results of post-hoc analyses 
comparing the most severe (YBOCS>30) unmedicated OCD patients to controls did not 
resemble the same pattern of medication effects. Nevertheless, the cortical abnormalities in 
currently medicated OCD patients could reflect persistent abnormalities related to increased 
OCD severity before treatment. In addition, medication effects persisted after adding a 
covariate correcting for illness severity (data not shown). The lack of association between 
severity according to the (C)Y-BOCS and cortical measures could be due to medication 
reducing the symptom severity. Additionally, current symptom severity might not be optimal 
to capture the long-term disease severity.
With regard to retrospectively ascertained age at onset in adult patients, the lack of inferior 
parietal abnormalities in the adult sample with childhood onset might be explained by 
insufficient power. When looking at the effect sizes, decreased cortical thickness of the 
inferior parietal cortex was present in adult patients with a childhood disease onset 
compared to healthy controls, but at a less stringent significance threshold. The effect size 
was even slightly larger than the effect size of the main group comparison suggesting a 
power issue, rather than a lack of inferior parietal abnormalities. In contrast, adult illness 
onset was associated with widespread thinner cortices. The adult-onset group is older than 
the childhood-onset group, but also has a higher percentage of medicated patients. Post hoc 
analyses showed that these effects mostly disappear when correcting for medication status 
suggesting that these findings are mainly driven by medication.
Cortical structural deficits were not associated with comorbid depression or anxiety. The 
effect sizes of these small sub-groups with comorbid anxiety or depression indicate 
insufficient statistical power to address this issue with certainty. From a clinical point of 
view comorbid Tourette’s syndrome and attention-hyperactivity-deficit disorder are more 
relevant to study in children with OCD. Because of the lack of systematic clinical 
investigation of comorbidities we were unable to investigate this. Common comorbidities 
may be more aptly termed interacting variables, as they interact in complex ways. Therefore, 
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excluding comorbid conditions will ignore complex interactions that are often integral to the 
disorder.
Surface area
The transverse temporal cortex surface area deficit was consistent across analyses in adult 
OCD. This region belongs to the primary auditory cortex and has not been implicated in 
OCD pathophysiology before. Lower cortical thickness and lower volume of this region 
have been associated with auditory hallucinations in schizophrenia (40). Prior approaches to 
detect structural alteration in this region may have been hampered by small samples or the 
modest sensitivity of conventional volumetric approaches. The advantage of high statistical 
power allows us to examine abnormalities throughout the brain without the need to pre-
specify regions of interest and thus identify new regions putatively associated with the 
disorder. Further research is necessary understand the involvement of the transverse 
temporal cortex in OCD.
Medicated children with OCD had smaller left and right hemisphere total surface area, 
reflecting a diffuse pattern of frontal surface area deficits. These findings cannot be 
explained by differences in illness severity, comorbidity or age at onset (Supplementary 
Table S35). This may indicate delayed cortical maturation, although longitudinal studies are 
needed to prove that. The surface area of these frontal regions matures over a more 
prolonged time course during adolescence (41) and may be especially prone to a 
maturational delay in pediatric OCD, possibly affected by medication status. Such delayed 
maturation may alter functional connections with other regions through decreases in growth 
and branching of dendritic trees and the number of synapses associated with gray matter 
volume (42), which may persist into adult OCD even if surface area measures normalize 
when transitioning into adulthood. The absence of cortical surface area abnormalities in the 
adult OCD patients with a childhood-onset could indicate such normalization.
Limitations
When combining existing data across samples worldwide, data collection protocols were not 
prospectively harmonized. Imaging acquisition protocols and clinical assessments therefore 
differed across studies, which limits analysis of sources of heterogeneity.As another 
limitation we note that the T1-weighted scans were not collected with direct measures of 
head motion, which might have introduced potential motion-induced bias in cortical 
measures (43).
In addition, FreeSurfer measurements may benefit from manual edits if they are made 
consistently across all scans. Although we had an extensive standardized protocol for quality 
checking, the individual sites did not perform manual editing, as this could have resulted in 
increased variation in the data across sites due to high number of sites involved.
We reported widespread medication effects both in adults and children with OCD. However, 
the current study did not allow a reliable investigation of medication effects because of its 
cross-sectional design and lack of detailed information on history, duration, type, and dosage 
of psychotropic treatment. We therefore must interpret our results with caution and cannot 
make any premature conclusions about the effect of anti-OCD medication. Further efforts, 
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e.g. intervention studies with comparisons before and after medication, are required to draw 
valid conclusions on the impact of medication use on cortical structure.
Several studies using a symptom dimensional approach suggest that symptom dimensions 
may be mediated by partially distinct neural systems (44; 45). Except for the association 
between a higher surface area of the left cuneus and ordering/symmetry dimension in 
children, we did not detect thickness or surface area effects of the other symptom 
dimensions in children and adults. An explanation may be that symptom subtype differences 
are more focal and remain undetected in this atlas-based analysis. On the other hand, 
variance in use of instruments across the participating sites might have led to suboptimal 
harmonization of the symptom dimension scores and therefore might explain the absence of 
associations with the symptom dimensions in our study. During harmonization, we defined 
symptom dimensions in a binary manner as absent or present for each participant based on 
the (C)Y-BOCS symptom checklist, whereas prior studies have correlated the dimension 
scores with cortical measures.
As a minor limitation, we note that followed from a natural selection of study samples we 
split the data in adults (≥ 18 years) and children (< 18 years), which might not be the optimal 
cut-off related to the onset and evolution of OCD (46; 47) In addition, the pediatric sample 
represents a wide age range, including puberty. We did not have enough data on pubertal 
stage to take pubertal development into account. Given the role of hormonal influence on 
cortical structures this will be useful to pursue in future research.
Conclusion
The parietal cortex was implicated in both adult and pediatric OCD. These results support 
the hypothesis that the pathophysiology of OCD cannot be solely explained by alterations of 
the classical CSTC regions and emphasize the importance of parietal regions. Widespread 
cortical thickness abnormalities were found in medicated adult OCD patients, while more 
pronounced surface area deficits were found in medicated pediatric OCD patients. Cortical 
thickness and surface area represent distinct features of the cortex and may be differentially 
affected by OCD and possibly moderated by medication status. Further work, using 
longitudinal designs, and incorporating genetic and environmental variables, will be useful 
in understanding the precise mechanisms underlying the structural abnormalities preceding 
the onset of the illness and occurring during the course of the illness.
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Mega-analysis effect sizes for regions that showed a significant (q<0.05) difference in 
cortical thickness between adult OCD patients and healthy controls. Negative effect sizes d 
(red) indicate cortical thinning in OCD compared to controls
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Mega-analysis effect sizes for regions that showed a significant (q<0.05) difference in 
cortical thickness between pediatric OCD patients and healthy controls. Negative effect sizes 
d (red) indicate cortical thinning in OCD compared to controls
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Mega-analysis effect sizes for regions that showed a significant (q<0.05) difference in 
cortical thickness between adult medicated OCD patients and healthy controls. Negative 
effect sizes d (red) indicate cortical thinning in OCD compared to controls.
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Mega-analysis effect sizes for regions that showed a significant (q<0.05) difference in 
cortical surface area between pediatric medicated OCD patients and healthy controls. 
Negative effect sizes d (red) indicate reduced cortical surface area in OCD compared to 
controls.
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Table 1:
Mega-analytical demographics and clinical characteristics.














* 9.7 13.8 2.5 13.6 2.6
OCD illness severity score
a 24.4 6.9 21.4 7.3
Age at onset of clinical symptoms 
(years)
19.8 9.1 10.6 3.1
N % N % N % N %
Male 756 50.5 713 49.7 220 54.1 164 50.6
Medication use at time of scan 646 43,1 183 45.0
Current comorbid anxiety 
disorder
224 15.0 132 32.4
Current comorbid major 
depression diagnosis
167 11.1 29 7.1
Current comorbid Tourette’s 
Disorder
**
24 1.6 30 7.4
Current comorbid ADHD
** 13 0.9 42 10.3
Current comorbid ASD
** 0 0 5 1.2
OCD symptom dimensions
b
Aggressive/checking 927 61.9 195 47.9
Contamination/cleaning 791 52.8 172 42.3
Symmetry/ordering 640 42.7 181 44.5
Sexual/religious 487 32.5 92 22.6
Hoarding 379 25.3 92 22.6
a
As measured with the Yale-Brown Obsessive Compulsive Scale (YBOCS) total score
b
As measured with the YBOCS symptom checklist
*
Statistically significant difference (t(2932)=−4.222, p<0.001)
**
not assessed in each sample
abbreviations: ADHD attention deficit hyperactivity disorder; ADS autism spectrum disorder
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